These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. Lamprecht A; Yamamoto H; Takeuchi H; Kawashima Y J Pharmacol Exp Ther; 2005 Oct; 315(1):196-202. PubMed ID: 15980057 [TBL] [Abstract][Full Text] [Related]
3. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. Nakase H; Okazaki K; Tabata Y; Chiba T J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874 [TBL] [Abstract][Full Text] [Related]
4. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. Lamprecht A; Ubrich N; Yamamoto H; Schäfer U; Takeuchi H; Maincent P; Kawashima Y; Lehr CM J Pharmacol Exp Ther; 2001 Nov; 299(2):775-81. PubMed ID: 11602694 [TBL] [Abstract][Full Text] [Related]
5. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Moulari B; Pertuit D; Pellequer Y; Lamprecht A Biomaterials; 2008 Dec; 29(34):4554-60. PubMed ID: 18790531 [TBL] [Abstract][Full Text] [Related]
6. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Meissner Y; Pellequer Y; Lamprecht A Int J Pharm; 2006 Jun; 316(1-2):138-43. PubMed ID: 16675176 [TBL] [Abstract][Full Text] [Related]
7. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. Lamprecht A; Yamamoto H; Takeuchi H; Kawashima Y J Control Release; 2005 May; 104(2):337-46. PubMed ID: 15907584 [TBL] [Abstract][Full Text] [Related]
8. [The preventive and therapeutic effects of low molecular weight heparin on DSS-induced colitis in mice]. He G; Ouyang Q Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):701-3. PubMed ID: 14619586 [TBL] [Abstract][Full Text] [Related]
9. Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice. Luo J; Cao J; Jiang X; Cui H Biomed Pharmacother; 2010 Sep; 64(7):441-5. PubMed ID: 20359854 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease. Shteingart S; Rapoport M; Grodzovski I; Sabag O; Lichtenstein M; Eavri R; Lorberboum-Galski H Gut; 2009 Jun; 58(6):790-8. PubMed ID: 18978179 [TBL] [Abstract][Full Text] [Related]
11. Colonic delivery of carboxyfluorescein by pH-sensitive microspheres in experimental colitis. Kietzmann D; Moulari B; Béduneau A; Pellequer Y; Lamprecht A Eur J Pharm Biopharm; 2010 Oct; 76(2):290-5. PubMed ID: 20600885 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis. Luo JY; Zhong Y; Cao JC; Cui HF Biomed Pharmacother; 2011 Mar; 65(2):111-7. PubMed ID: 21227626 [TBL] [Abstract][Full Text] [Related]
19. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]